Table 1.

Geometric mean concentrations of anti-SARS-CoV-2 spike IgG antibodies among healthcare workers who received the BNT162b2 mRNA COVID-19 vaccine, Israel, December 2020 to March 2021

		1st serological test (15–35 days post-vaccine dose 1)					2nd serological test (41–65 days post-vaccine dose 1)
Groups	n	n	Median age	Median days from dose 1	GMC (AU/ml)	95% CI	n	Median age	Median days from dose 1	GMC (AU/ml)	95% CI
Previously infected 1 dose	6	16a	42	21	773.4	449.1–1331.8	3	42	47	464.7	17.7–12 168.3
Previously infected 2 doses	19						16	42	50	570.6	380.6–855.6
Infected after dose 1	32	9	41	21	73.3	56.3–95.4	20	46	50	83.8	60.5–115.9
Infected after dose 2	3	–		–	–	–	2	45	56	230.2	22.9–2308.9
Uninfected 1 dose	22	516b	45	21	64.1	60.3–68.2	3	51	54	90.2	4.7–1721.7
Uninfected 2 doses	643						492	46	52	196	189–203.2
Overall	725	541	45	21	69.3	64.6–74.5	536	45	52	196.1	187.7–205

^aIncludes individuals who received one or two doses in total.

^bIncludes individuals who received one or two doses in total.